License and Collaboration Arrangements (Additional Information) (Details) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2022 USD ($)
Zai Lab | Research and Development Support
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues	$ 0.0
Future potential milestone payment receivable	91.0	$ 91.0
PAION AG
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Future potential milestone payment receivable	109.5	109.5
Everest Medicines Limited
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additional regulatory milestone payments receivable	8.0	8.0
Sales milestone payments receivable	$ 20.0	$ 20.0
Royalties payable period after first commercial sale of product		10 years
Everest Medicines Limited | Commercial Supply Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of reimbursed for direct and certain indirect manufacturing costs	110.00%
Deferred revenue	$ 2.8	$ 2.8
George Washington University
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty payable on net sales	6.00%
Percentage of royalty on payments received from sublicensees	15.00%
Harvard University
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty payable on net sales	5.00%
Percentage of royalty on payments received from sublicensees	20.00%
Clinical development and regulatory milestones amount payable	$ 15.1
Percentage of minimum royalty rate	4.50%
Percentage of maximum royalty based on achievement of annual net product sales thresholds	7.50%
Paratek Pharmaceuticals, Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty payable on net sales	2.25%
Claim expiration	2023-10